New shot could tame high cholesterol without statins
NCT ID NCT07473960
First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 1 time
Summary
This Phase 3 trial tests a new injectable drug called IBI306 in 198 Chinese adults with non-familial high cholesterol and mixed high lipids. Participants receive either IBI306 or a placebo every 2 or 4 weeks for 12 weeks. The main goal is to see how much the drug lowers LDL (bad) cholesterol compared to placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- IBI306 (a drug given as an injection every 2 or 4 weeks)
- What this could lead to
- If successful, this could provide a new treatment option to lower bad cholesterol and reduce heart disease risk for people with high cholesterol.
- What could go wrong
- This is a relatively small, early-stage Phase 3 trial in Chinese participants only, so results may not apply to other populations. The drug may not lower cholesterol enough or could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIXED HYPERLIPIDEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University Third Hospital
Beijing, Beijing Municipality, 100083, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.